Martin S Tallman Selected Research

Aligeron (AS 2)

11/2010	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
9/2010	Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
5/2008	Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
1/2008	Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
11/2006	Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin S Tallman Research Topics

Disease

125	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2022 - 03/2002
61	Neoplasms (Cancer) 03/2022 - 10/2002
58	Acute Promyelocytic Leukemia 01/2022 - 01/2002
54	Leukemia 01/2022 - 04/2002
33	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 08/2002
26	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/2022 - 10/2002
16	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 10/2002
12	Philadelphia Chromosome 01/2021 - 10/2002
11	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2019 - 10/2002
9	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2002
9	Hairy Cell Leukemia 01/2018 - 04/2002
8	Thrombocytopenia (Thrombopenia) 03/2022 - 06/2002
7	Hyperbilirubinemia 01/2021 - 03/2014
7	Hemorrhage 11/2019 - 03/2005
7	Drug-Related Side Effects and Adverse Reactions 06/2009 - 10/2003
6	Infections 10/2021 - 08/2002
6	Breast Neoplasms (Breast Cancer) 08/2011 - 07/2003
5	Febrile Neutropenia 03/2022 - 06/2007
5	Neutropenia 10/2021 - 02/2007
5	Anemia 01/2021 - 11/2005
5	Lymphoma (Lymphomas) 01/2020 - 10/2002
5	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 12/2019 - 12/2013
4	Hypersensitivity (Allergy) 01/2021 - 03/2014
4	Disease Progression 03/2013 - 09/2004
3	Pathologic Complete Response 12/2021 - 12/2006
3	Primary Myelofibrosis (Myelosclerosis) 10/2021 - 11/2010
3	Residual Neoplasm 01/2021 - 06/2011
3	Hyperglycemia 01/2021 - 01/2020
3	Fatigue 01/2020 - 05/2012
3	Headache (Headaches) 01/2020 - 01/2003
3	Multiple Myeloma 01/2016 - 10/2002
3	Chronic Renal Insufficiency 11/2012 - 09/2004
3	Leukocytosis (Pleocytosis) 12/2009 - 04/2005
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 09/2012
2	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 06/2007

Drug/Important Bio-Agent (IBA)

35	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 10/2002
22	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 01/2002
19	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 08/2002
18	AnthracyclinesIBA 11/2019 - 08/2002
13	Proteins (Proteins, Gene)FDA Link 10/2020 - 10/2002
12	Phosphotransferases (Kinase)IBA 10/2020 - 08/2003
12	Pharmaceutical PreparationsIBA 10/2015 - 10/2003
10	Gemtuzumab (Mylotarg)FDA Link 01/2018 - 03/2002
8	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2022 - 01/2003
8	Erythropoietin FDA Link 01/2021 - 10/2002
8	Imatinib Mesylate (Gleevec)FDA Link 02/2014 - 10/2002
7	venetoclaxIBA 01/2022 - 01/2018
7	Asparaginase (Elspar)FDA Link 01/2021 - 01/2003
7	enasidenibIBA 01/2021 - 10/2017
7	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 10/2009
6	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 10/2009
6	Immunoconjugates (Immunoconjugate)IBA 10/2020 - 10/2002
6	Alemtuzumab (Campath)FDA Link 01/2019 - 10/2002
6	Rituximab (Mabthera)FDA Link 01/2019 - 10/2002
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 07/2003
5	Monoclonal AntibodiesIBA 03/2022 - 10/2002
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021 - 12/2006
5	pegaspargase (Oncaspar)FDA Link 01/2021 - 03/2014
5	Biological ProductsIBA 10/2020 - 04/2004
5	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2018 - 06/2013
5	fludarabineIBA 01/2015 - 05/2004
5	Aligeron (AS 2)IBA 11/2010 - 11/2006
4	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2021 - 02/2008
4	InterferonsIBA 01/2021 - 04/2002
4	purineIBA 10/2015 - 10/2002
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2011 - 01/2004
3	ivosidenibIBA 01/2021 - 01/2020
3	midostaurinIBA 01/2021 - 01/2017
3	Interferon-alpha (Interferon Alfa)IBA 01/2021 - 05/2005
3	fms-Like Tyrosine Kinase 3IBA 10/2020 - 01/2013
3	Histones (Histone)IBA 01/2020 - 08/2006
3	Tyrosine Kinase InhibitorsIBA 12/2019 - 02/2017
3	alpha-hydroxyglutarateIBA 12/2018 - 12/2010
3	Protein Isoforms (Isoforms)IBA 12/2018 - 11/2015
3	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 08/2002
3	Biomarkers (Surrogate Marker)IBA 04/2017 - 05/2012
3	entinostat (MS 275)IBA 02/2016 - 10/2009
3	EnzymesIBA 01/2016 - 01/2010
3	Cladribine FDA LinkGeneric 06/2011 - 05/2004
3	Prednisone (Sone)FDA LinkGeneric 11/2010 - 01/2003
3	Eukaryotic Initiation Factor-4EIBA 10/2010 - 02/2005
3	ArsenicIBA 09/2010 - 07/2008
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2022 - 01/2020
2	CholesterolIBA 01/2022 - 05/2007
2	ChromatinIBA 01/2022 - 10/2014
2	tipifarnib (R115777)IBA 12/2021 - 03/2014
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2021 - 12/2019

Therapy/Procedure

108	Therapeutics 12/2021 - 04/2002
68	Drug Therapy (Chemotherapy) 01/2022 - 06/2002
17	Cell Transplantation 01/2022 - 02/2008
13	Hematopoietic Stem Cell Transplantation 12/2021 - 07/2003
12	Induction Chemotherapy 11/2021 - 06/2002
12	Transplantation 01/2021 - 07/2003
8	Homologous Transplantation 01/2018 - 02/2008
6	Salvage Therapy 12/2021 - 05/2004
4	Immunotherapy 10/2020 - 01/2016
4	Consolidation Chemotherapy 11/2019 - 02/2006
4	Autologous Transplantation 05/2011 - 02/2006
3	Stem Cell Transplantation 01/2021 - 07/2003
3	Adjuvant Chemotherapy 01/2010 - 07/2003